StreetInsider.com News Articles

Disc Medicine (IRON) Reiterated at Overweight by Cantor Fitzgerald on Selcodebart Potential

Tue, 01 Sep 2026 07:10:27 -0400

Cantor Fitzgerald analyst Kristen Kluska reiterated an Overweight rating and $125.00 price target on Disc Medicine (NASDAQ: IRON).

The analyst commented, "Our physician survey supports broad commercial adoption, with physicians indicating, on average, they'd treat ~44% of patients with MF anemia with selcodebart. Using this estimate across pricing assumptions of $200-300K/yr could lead to peak sales of $1.93B-$2.89B alone, based on our analysis. Even in a more conservative simulation (which also maintains our estimates for the rest of the pipeline), 15% (U.S.) and 14% (EU) peak penetration at 70% PoS could bring our equity valuation up to $148/ share. If bitopertin

Disc Medicine Announces Multiple Presentations Across Portfolio at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting

Mon, 31 Aug 2026 18:00:00 -0400

WATERTOWN, Mass., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced that it will present data from multiple clinical programs, including an oral presentation of initial data from the RESTORE-PV trial of DISC-3405 in patients with polycythemia vera (PV), at the SOHO Annual Meeting, which will be held in Houston, Texas on September 9-12, 2026.

“We are excited to share the first clinical data from our Phase 2 study of DISC-3405 in polycythemia

Disc Medicine Announces Multiple Presentations Across Portfolio at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting

Mon, 31 Aug 2026 18:00:00 -0400

“We are excited to share the first clinical data from our Phase 2 study of DISC-3405 in polycythemia

Disc Medicine Announces Multiple Presentations Across Portfolio at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting

Mon, 31 Aug 2026 18:00:00 -0400

“We are excited to share the first clinical data from our Phase 2 study of DISC-3405 in polycythemia

Disc Medicine Announces Multiple Presentations Across Portfolio at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting

Mon, 31 Aug 2026 18:00:00 -0400

“We are excited to share the first clinical data from our Phase 2 study of DISC-3405 in polycythemia

Form 4 Disc Medicine, Inc. For: Aug 24 Filed by: Yu Jonathan Yen-Wen

Wed, 26 Aug 2026 20:10:00 -0400

si-local-file:///var/storage/secattach/20260826/26983262.html

Form 4 Disc Medicine, Inc. For: Aug 24 Filed by: Yu Jonathan Yen-Wen

Wed, 26 Aug 2026 20:10:00 -0400

si-local-file:///var/storage/secattach/20260826/26983262.html

Form 4 Disc Medicine, Inc. For: Aug 17 Filed by: Quisel John D

Tue, 18 Aug 2026 18:57:00 -0400

si-local-file:///var/storage/secattach/20260818/26945871.html

Form 4 Disc Medicine, Inc. For: Aug 17 Filed by: Quisel John D

Tue, 18 Aug 2026 18:57:00 -0400

si-local-file:///var/storage/secattach/20260818/26945871.html

Form 144 Disc Medicine, Inc. Filed by: Quisel John D

Mon, 17 Aug 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260817/26938398.html

Form 144 Disc Medicine, Inc. Filed by: Quisel John D

Mon, 17 Aug 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260817/26938398.html

Disc Medicine (IRON) PT Raised to $90 at Morgan Stanley

Mon, 17 Aug 2026 08:58:13 -0400

Morgan Stanley analyst Sean Laaman raised the price target on Disc Medicine (NASDAQ: IRON) to $90.00 (from $85.00) while maintaining a Overweight rating.

Form 4 Disc Medicine, Inc. For: Aug 12 Filed by: Yu Jonathan Yen-Wen

Fri, 14 Aug 2026 19:15:00 -0400

si-local-file:///var/storage/secattach/20260814/26933208.html

Form 4 Disc Medicine, Inc. For: Aug 12 Filed by: Yu Jonathan Yen-Wen

Fri, 14 Aug 2026 19:15:00 -0400

si-local-file:///var/storage/secattach/20260814/26933208.html

Form 4 Disc Medicine, Inc. For: Aug 06 Filed by: Khara Rahul

Fri, 07 Aug 2026 17:32:00 -0400

si-local-file:///var/storage/secattach/20260807/26892337.html

Form 4 Disc Medicine, Inc. For: Aug 06 Filed by: Khara Rahul

Fri, 07 Aug 2026 17:32:00 -0400

si-local-file:///var/storage/secattach/20260807/26892337.html

Form 144 Disc Medicine, Inc. Filed by: Khara Rahul

Thu, 06 Aug 2026 16:28:00 -0400

si-local-file:///var/storage/secattach/20260806/26884644.html

Form 144 Disc Medicine, Inc. Filed by: Khara Rahul

Thu, 06 Aug 2026 16:28:00 -0400

si-local-file:///var/storage/secattach/20260806/26884644.html

Form SCHEDULE 13G/A Disc Medicine, Inc. Filed by: FMR LLC

Thu, 06 Aug 2026 10:21:00 -0400

si-local-file:///var/storage/secattach/20260806/26881106.html

Form SCHEDULE 13G/A Disc Medicine, Inc. Filed by: FMR LLC

Thu, 06 Aug 2026 10:21:00 -0400

si-local-file:///var/storage/secattach/20260806/26881106.html

Disc Medicine (IRON) PT Raised to $120 at H.C. Wainwright

Thu, 06 Aug 2026 06:55:03 -0400

H.C. Wainwright analyst Douglas Tsao raised the price target on Disc Medicine (NASDAQ: IRON) to $120.00 (from $118.00) while maintaining a Buy rating.

Disc Medicine (IRON) Tops Q2 EPS by 17c

Thu, 30 Jul 2026 08:44:40 -0400

Disc Medicine (NASDAQ: IRON) reported Q2 EPS of ($1.54), $0.17 better than the analyst estimate of ($1.71).

For earnings history and earnings-related data on Disc Medicine (IRON) click here.

Form 10-Q Disc Medicine, Inc. For: Jun 30

Thu, 30 Jul 2026 08:35:00 -0400

si-local-file:///var/storage/secattach/20260730/26839650.html

Form 10-Q Disc Medicine, Inc. For: Jun 30

Thu, 30 Jul 2026 08:35:00 -0400

si-local-file:///var/storage/secattach/20260730/26839650.html

Form 8-K Disc Medicine, Inc. For: Jul 30

Thu, 30 Jul 2026 08:33:00 -0400

si-local-file:///var/storage/secattach/20260730/26839625.html